Shared from parkinsonsnewstoday.com.
Annovis Bio has scheduled a January meeting with the U.S. Food and Drug Administration (FDA) to discuss buntanetap as a treatment for dementia due to Parkinson’s disease.
The meeting will include discussions about potential clinical trial design, the criteria that will be used to determine which patients to enroll, and the data required to support an application seeking approval of buntanetap for Parkinson’s dementia.
“We are pleased with such proactive engagement with the FDA on our [Parkinson’s disease dementia] program, which represents a significant opportunity to address an underserved patient population,” Maria Maccecchini, PhD, Annovis’ president and CEO, said in a company press release. “The scheduled January meeting marks a key milestone for our pipeline, underscoring buntanetap’s potential across multiple neurodegenerative indications and the strength of our scientific approach.”